BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NCR300 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of NCR300\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06441084-2984@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:NCR300: Phase 1 readout est. (NCT06441084)
DESCRIPTION:NCR300\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Trial to E
 valuate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acut
 e Myeloid Leukemia（AML) After Transplantation\nEstimated primary complet
 ion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ncr300#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06441084
URL:https://assetmemo.bio/drug/ncr300#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
